FDA Approval Alert: The Need-to-Know | Vimseltinib in Tenosynovial Giant Cell Tumors

In February 2025, the FDA approved vimseltinib, a kinase inhibitor, in the treatment of patients with tenosynovial giant cell tumor, in which surgical resection may cause worsening functional limitation or severe morbidity.

FDA Approves Vimseltinib in Tenosynovial Giant Cell Tumor
FDA Approves Vimseltinib in Tenosynovial Giant Cell Tumor
Article
Feb 14, 2025 8:51 PM
Vimseltinib elicited an ORR of 40% vs 0% of matching placebo in patients with tenosynovial giant cell tumor in the phase 3 MOTION trial.